The clinical management of pheochromocytomas and paragangliomas (PPGLs) has long been one of the most daunting challenges in the field of endocrinology and oncology. These rare neuroendocrine tumors, which arise from chromaffin cells of the adrenal medulla or extra-adrenal sympathetic and parasympathetic ganglia, present a unique paradox to clinicians: while approximately 75% of these tumors remain localized, every single case must be treated as having metastatic potential. This is because, despite decades of research, the medical community currently lacks reliable biochemical, histological, or genetic markers that can definitively predict which tumors will remain indolent and which will aggressively spread.
In a groundbreaking paper published in The Journal of Clinical Endocrinology & Metabolism (JCEM), Dr. Camilo Jimenez and his colleagues at the Department of Endocrine Neoplasia and Hormonal Disorders at the University of Texas MD Anderson Cancer Center have introduced a novel algorithmic framework designed to navigate this complexity. By integrating clinical phenotypes with tumor genotypes, the team aims to standardize the approach to systemic therapy, providing a roadmap for clinicians to choose between traditional cytotoxic chemotherapy and emerging targeted treatments. This development comes at a critical juncture as the therapeutic landscape for PPGLs shifts from broad-spectrum toxic agents to highly specific molecular inhibitors and radiopharmaceuticals.
The Diagnostic Dilemma and the Limitations of Current Staging
The traditional TNM (Tumor, Node, Metastasis) staging system, which is the gold standard for most solid tumors, has proven insufficient for PPGLs. While the system accounts for primary tumor size and anatomical location, it fails to capture the biological heterogeneity that dictates the clinical course of neuroendocrine disease. Consequently, clinicians often find themselves in a reactive position, waiting for metastatic spread to occur before initiating systemic interventions.
The urgency for a more sophisticated approach is driven by the fact that metastatic PPGL is associated with significant morbidity. The tumors often overproduce catecholamines—norepinephrine, epinephrine, and dopamine—leading to "catecholamine storms" characterized by severe hypertension, palpitations, and potential organ failure. For years, the only systemic option for advanced disease was the CVD regimen: a combination of cyclophosphamide, vincristine, and dacarbazine. While CVD can be effective in reducing tumor burden and controlling symptoms, its high toxicity profile, including myelosuppression and neuropathy, often limits its long-term use, especially in patients already weakened by the hormonal effects of the tumor.
A New Framework: The Jimenez Treatment Algorithm
Dr. Jimenez’s team developed an algorithm that moves away from a "one-size-fits-all" approach. The framework begins by classifying patients into one of four distinct groups based on their molecular profile. This genetic stratification is essential because the underlying mutation—whether it be in the succinate dehydrogenase (SDH) subunits, the Von Hippel-Lindau (VHL) gene, or other pathways—often determines how the tumor will respond to specific drugs.
Once the molecular profile is established, the algorithm subclassifies the disease based on its rate of progression. This "kinetic" assessment is vital; a slow-growing tumor may be managed with less aggressive, targeted therapies, while a rapidly progressing malignancy may still require the "heavy lifting" of cytotoxic chemotherapy. Finally, the algorithm offers a tiered list of first-line and second-line options, including radioligands and tyrosine-kinase inhibitors (TKIs), or directs the patient toward relevant clinical trials.
Chronology of a Complex Case: From Chemotherapy to Belzutifan
To demonstrate the practical utility of the algorithm, the JCEM paper details the case of a 67-year-old male who presented in 2020 with a constellation of symptoms including progressive fatigue, severe hypertension, and abdominal pain. Imaging revealed a large, highly vascular primary tumor that was deemed unresectable. The patient was diagnosed with paraganglioma syndrome type 4, a condition often linked to mutations in the SDHB gene.
The initial strategy followed the algorithm’s guidance for high-burden, symptomatic disease: the patient was started on CVD chemotherapy. The goal was neoadjuvant—to shrink the tumor enough to allow for surgical resection. The treatment was successful, and following surgery, the patient remained disease-free for two years. However, when the tumor eventually recurred, its behavior had changed. It was no longer rapidly progressing, but it was now incurable and widespread.
In this second phase, the team shifted strategies. Rather than returning to the toxic CVD regimen, they opted for radiopharmaceutical therapy with Lutetium-177-DOTATATE (commonly known as Lutathera). This treatment targets somatostatin receptors, which are frequently overexpressed in PPGLs. While the administration was complex and required an intensive care unit (ICU) stay due to the risk of a catecholamine crisis during the infusion, it offered a more targeted approach.
The final stage of the patient’s journey highlights the rapid evolution of the field. In 2025, the U.S. Food and Drug Administration (FDA) approved belzutifan for the treatment of PPGLs characterized by pseudohypoxia. Belzutifan is a selective small-molecule inhibitor of hypoxia-inducible factor 2α (HIF2α), a protein that drives tumor growth in certain genetic clusters. Transitioning to this oral medication provided the patient with sustained symptomatic improvement and tumor stability, illustrating how the algorithm adapts as new therapies enter the market.
The Rise of Targeted Therapies and Radiopharmaceuticals
The shift toward targeted therapy represents a major milestone in neuroendocrine oncology. For decades, the medical community relied on anecdotal evidence and small case series to guide PPGL treatment. The introduction of radioligands like I-131 MIBG (Azedra) and Lutetium-177-DOTATATE has changed the prognosis for many. These agents deliver radiation directly to the tumor cells, sparing much of the surrounding healthy tissue.
However, as Dr. Jimenez notes, these therapies are not without risks. The "hormonal flare" that can occur during the administration of radiopharmaceuticals requires specialized centers with the capability to manage hypertensive emergencies. Furthermore, tyrosine-kinase inhibitors (TKIs) like sunitinib and cabozantinib, while effective in blocking the blood supply to these vascular tumors, carry their own set of side effects, including fatigue and gastrointestinal distress. The Jimenez algorithm helps clinicians weigh these trade-offs by prioritizing efficacy and safety based on the individual patient’s tumor biology.
Global Implications and the Democratization of Care
One of the most significant aspects of the MD Anderson team’s work is its focus on global applicability. Dr. Jimenez, who serves on the European Society for Medical Oncology (ESMO) guideline panel, acknowledges that the "gold standard" of care in the United States may not be attainable in every country. Molecular subtyping, PET/CT imaging with Gallium-68 DOTATATE, and access to new drugs like belzutifan require infrastructure and financial resources that are often absent in lower-resource settings.
"The algorithm is designed with everybody around the world in mind," Jimenez explained. In settings where advanced genetic testing or expensive radiopharmaceuticals are unavailable, the algorithm still provides value by encouraging clinicians to think about the rate of disease progression and the most "optimal available" choice. In many parts of the world, CVD chemotherapy remains the most realistic option. The algorithm validates this choice when necessary while providing a framework for when and how to transition to other therapies if they become accessible.
The Challenge of Rare Disease Research
The development of this algorithm also highlights the inherent difficulties in researching "orphan" diseases. Because metastatic PPGL is so rare, recruiting enough patients for large-scale, Phase 3 randomized controlled trials—the gold standard of medical evidence—is nearly impossible for a single institution. It requires massive international cooperation and significant funding, both of which are difficult to secure for rare conditions.
Dr. Jimenez emphasizes that while the data supporting some of the algorithm’s recommendations may not yet reach the level of a Phase 3 trial, they are based on the strongest available evidence from Phase 2 studies and expert consensus. The inclusion of belzutifan, for instance, followed 25 years of research into the VHL-HIF2α pathway. "It’s a lovely medication, but we still need to do more work," Jimenez said, noting that while it is a major step forward, it is not a cure.
Future Directions and Clinical Outlook
The publication of "Approach to the patient with metastatic pheochromocytoma and paraganglioma: advances in systemic therapy" marks a transition from empirical treatment to precision medicine in the field of endocrinology. The MD Anderson team’s work suggests that the future of PPGL management lies in even more granular molecular profiling, perhaps eventually utilizing liquid biopsies to monitor tumor evolution in real-time.
As the medical community moves toward 2026 and beyond, the focus will likely shift toward combination therapies—pairing radiopharmaceuticals with targeted molecular inhibitors to prevent the development of resistance. For now, the Jimenez algorithm serves as an essential bridge, filling the gap between current clinical limitations and the promise of future breakthroughs.
The ultimate goal, as stated by the authors, is inclusivity. By providing a structured way to think about these complex tumors, the algorithm empowers clinicians worldwide to offer the best possible care to a diverse and often overlooked patient population. As the case study of the 67-year-old patient demonstrates, the path to managing metastatic PPGL is rarely linear, but with a robust framework in place, clinicians can navigate the twists and turns of the disease with greater confidence and clarity.
